Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. (Q38405712)
Jump to navigation
Jump to search
scientific article published on July 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. |
scientific article published on July 2006 |
Statements
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial (English)
Stephen I Rennard
Mitchell Nides
Cheryl Oncken
Salomon Azoulay
Clare B Billing
Eric J Watsky
Jason Gong
Kathryn E Williams
Karen R Reeves
Varenicline Phase 3 Study Group